Prelude Therapeutics (PRLD) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Prelude Therapeutics is the larger company by market cap ($260.2 million vs $252.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRLD | VCRE |
|---|---|---|
| Share price | $3.26 | $8.98 |
| Market cap | $260.16M | $252.92M |
| 1-day change | -1.81% | -1.21% |
| YTD return | +12.41% | — |
| 1-year return | +173.95% | — |
| 5-year return | -81.39% | — |
| EPS (TTM) | $-0.73 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $12.14M | — |
| Revenue growth (YoY) | +73.43% | — |
| Net income (latest FY) | $-99.50M | — |
| Operating margin | -861.33% | — |
| Net margin | -819.59% | — |
| 52-week high | $6.83 | $17.80 |
| 52-week low | $1.16 | $7.88 |
| Distance from 52-week high | -52.27% | -49.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +182.21% | +223.83% |
| Average volume | 487.98K | 17.84K |
| Shares outstanding | 65.08M | 28.16M |
| Employees | 79 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 46 employees
PRLD vs VCRE FAQ
Which is bigger, Prelude Therapeutics or Vicore Pharma AB?
Prelude Therapeutics (PRLD) is larger, with a market capitalization of $260.16M compared with $252.92M for Vicore Pharma AB (VCRE).
Are Prelude Therapeutics and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.